-
![6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist](/abs-image/US/2013/11/12/US08580780B2/abs.jpg.150x150.jpg)
1.发明授权6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist 失效6-取代的2,3,4,5四氢-1H-苯并[d]吖庚因，为5-HT 2C受体激动剂公开(公告)号：US08580780B2
公开(公告)日：2013-11-12
申请号：US13192707
申请日：2011-07-28
申请人： John Gordon Allen , Karin Briner , Christopher Stanley Galka , Maria Angeles Martinez-Grau , Matthew Robert Reinhard , Michael John Rodriguez , Roger Ryan Rothhaar , Michael Wade Tidwell , Frantz Victor , Deyi Zhang , Steven Armen Boyd , Arundhati S. Deo , Wai-Man Lee , Christopher Stephen Siedem , Ajay Singh
发明人： John Gordon Allen , Karin Briner , Christopher Stanley Galka , Maria Angeles Martinez-Grau , Matthew Robert Reinhard , Michael John Rodriguez , Roger Ryan Rothhaar , Michael Wade Tidwell , Frantz Victor , Deyi Zhang , Steven Armen Boyd , Arundhati S. Deo , Wai-Man Lee , Christopher Stephen Siedem , Ajay Singh
IPC分类号： A61P3/04 , A61P25/22 , A61P25/24 , A61P25/30 , A61K31/55 , C07D223/16 , C07D401/12 , C07D417/12 , C07D413/12 , C07D403/12 , C07D409/12 , C07D405/12 , C07D413/14 , C07D417/06 , C07D403/06
CPC分类号： C07D223/16 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12
摘要： The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
摘要翻译： 本发明提供式I的6-取代2,3,4,5-四氢-1H-苯并[d]吖庚因作为选择性5-HT 2C受体激动剂，用于治疗5-HT 2C相关病症，包括肥胖，强迫症/强迫症 ，抑郁症和焦虑症：其中：R6为-S-R14; 和其它取代基如说明书中所定义。
-
公开(公告)号：US20120282219A1
公开(公告)日：2012-11-08
申请号：US13541436
申请日：2012-07-03
申请人： ROBERT EDWARD BABINE , SHU HUI CHEN , IVAN COLLADO , CRISTINA GARCIA-PAREDES , JOHN IRVIN GLASS , DEQI GUO , LING JIN , JASON ERIC LAMAR , RAYMOND SAMUEL PARKER, III , NANCY JUNE SNYDER , XICHENG DAVID SUN , MARK JOSEPH TEBBE , FRANTZ VICTOR , Q. MAY WANG , YVONNE YEE MAI YIP , ROBERT B. PERNI , LUC FARMER
发明人： ROBERT EDWARD BABINE , SHU HUI CHEN , IVAN COLLADO , CRISTINA GARCIA-PAREDES , JOHN IRVIN GLASS , DEQI GUO , LING JIN , JASON ERIC LAMAR , RAYMOND SAMUEL PARKER, III , NANCY JUNE SNYDER , XICHENG DAVID SUN , MARK JOSEPH TEBBE , FRANTZ VICTOR , Q. MAY WANG , YVONNE YEE MAI YIP , ROBERT B. PERNI , LUC FARMER
IPC分类号： A61K38/07 , C07D209/52 , C12N5/073 , A61P31/14 , A61K38/20 , C12N9/99 , C07K5/117 , A61K38/21
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及可用作蛋白酶抑制剂的肽模拟化合物，特别是作为丝氨酸蛋白酶抑制剂，更具体地，涉及丙型肝炎NS3蛋白酶抑制剂; 中间体; 它们的制备包括对中间体的新的立体选择性方法。 本发明还涉及药物组合物和使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染有关的生理病症的患者的方法。 还提供了药物组合，除一种或多种HCV丝氨酸蛋白酶抑制剂外还包含一种或多种表现出抗HCV活性的干扰素和/或一种或多种具有抗HCV活性的化合物和药学上可接受的载体，以及用于治疗或预防的方法 使用该组合物的患者中的HCV感染。 本发明还涉及用于治疗或预防患者HCV感染的试剂盒或药物包装。
-
![6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists](/abs-image/US/2011/07/19/US07981882B2/abs.jpg.150x150.jpg)
3.发明授权6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists 有权6-N-连接的杂环取代的2,3,4,5-四氢-1H-苯并[d]吖庚因，为5-HT 2C受体激动剂公开(公告)号：US07981882B2
公开(公告)日：2011-07-19
申请号：US11995212
申请日：2006-09-01
申请人： Karin Briner , Anne Marie Camp , Alan Cornell , Michael Philip Mazanetz , Roger Ryan Rothhaar , Frantz Victor , Andrew Caerwyn Williams , Deyi Zhang
发明人： Karin Briner , Anne Marie Camp , Alan Cornell , Michael Philip Mazanetz , Roger Ryan Rothhaar , Frantz Victor , Andrew Caerwyn Williams , Deyi Zhang
IPC分类号： A61P25/24 , A61K31/55 , C07D403/04 , C07D405/14 , C07D409/14 , C07D223/16 , C07D401/14
CPC分类号： C07D403/04 , C07D223/16 , C07D401/14 , C07D405/14 , C07D409/14
摘要： The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
摘要翻译： 本发明提供式I的6-取代2,3,4,5-四氢-1H-苯并[d]吖庚因作为选择性5-HT 2C受体激动剂，用于治疗5-HT 2C相关病症，包括肥胖，强迫症/强迫症 ，抑郁症和焦虑症：式（I）其中：R6选自（a，b，c，d，e）和其它取代基如说明书中所定义。
-
公开(公告)号：US07820671B2
公开(公告)日：2010-10-26
申请号：US10344112
申请日：2001-08-31
申请人： Robert Edward Babine , Shu Hui Chen , Ivan Collado , Cristina Garcia-Paredes , John Irvin Glass , Deqi Guo , Ling Jin , Jason Eric Lamar , Raymond Samuel Parker, III , Nancy June Snyder , Xicheng David Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Robert B. Perni , Luc Farmer
发明人： Robert Edward Babine , Shu Hui Chen , Ivan Collado , Cristina Garcia-Paredes , John Irvin Glass , Deqi Guo , Ling Jin , Jason Eric Lamar , Raymond Samuel Parker, III , Nancy June Snyder , Xicheng David Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Robert B. Perni , Luc Farmer
IPC分类号： A61K31/497 , C07D241/02
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
-
公开(公告)号：US20050222206A1
公开(公告)日：2005-10-06
申请号：US10509770
申请日：2003-03-27
申请人： Michael Cohen , Daniel Kohlman , Sidney Liang , Vincent Mancuso , Yao-Chang Xu , Bai-Ping Ying , DeAnna Zacherl , Deyi Zhang , Frantz Victor
发明人： Michael Cohen , Daniel Kohlman , Sidney Liang , Vincent Mancuso , Yao-Chang Xu , Bai-Ping Ying , DeAnna Zacherl , Deyi Zhang , Frantz Victor
IPC分类号： A61K31/4545 , A61K31/506 , A61P15/00 , A61P15/10 , A61P17/14 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/32 , A61P25/34 , A61P43/00 , C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D41/02
CPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14
摘要： The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
摘要翻译： 本发明涉及式I化合物或其药学上可接受的酸加成盐，其中： R 1是C 1 -C 6烷基，取代的C 1 -C 6亚烷基 烷基，C 3 -C 7环烷基，取代的C 3 -C 7环烷基，C 1 -C 3烷基， 取代的C 3 -C 3烷基，取代的C 3 -C 3烷基，C 1 -C 3烷基，C 3 -C 3 - 苯基，取代的苯基，杂环或取代的杂环; R 2是氢，C 1 -C 3烷基，C 3 -C 6烷基，C 3 -C 3烷基，C 3 -C 3烷基， 或者式II的基团R 3是氢或C 1 -C 6烷基， C 1 -C 3烷基; R 4是氢，卤素或C 1 -C 3烷基; R 5是氢或C 1 -C 3烷基; R 5是氢或C 1 -C 3烷基; R 6是氢或C 1 -C 6烷基; n为1〜6的整数。 本发明的化合物可用于活化5-HT 1F受体，抑制神经元蛋白质外渗，以及治疗或预防哺乳动物偏头痛。 本发明还涉及合成式I化合物中的中间体的方法。
-
公开(公告)号：US5891874A
公开(公告)日：1999-04-06
申请号：US868760
申请日：1997-06-04
申请人： Joseph Matthew Colacino , Beverly Ann Heinz , Louis Nickolaus Jungheim , Shawn Christopher Miller , Wayne Alfred Spitzer , Joseph Chiou-chung Tang , Mark Joseph Tebbe , Frantz Victor
发明人： Joseph Matthew Colacino , Beverly Ann Heinz , Louis Nickolaus Jungheim , Shawn Christopher Miller , Wayne Alfred Spitzer , Joseph Chiou-chung Tang , Mark Joseph Tebbe , Frantz Victor
IPC分类号： A61K31/415 , C07D235/06 , C07D235/30 , C07D409/12 , A61K31/535 , A61K31/445 , C07D403/02 , C07D417/00
CPC分类号： C07D409/12 , C07D235/30
摘要： A series of benzimidazole compounds having the following general structure are provided which inhibit the growth of picornaviruses (e.g., rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus) and flaviviruses (e.g., hepatitis C and bovine diarrheal virus). ##STR1## A method for inhibiting picornaviruses and flaviviruses is also provided which includes administering to a host an effective amount of the inventive benzimidazole compounds.
摘要翻译： 提供了一系列具有以下一般结构的苯并咪唑化合物，其抑制小核糖核酸病毒（例如，鼻病毒，肠病毒，脊髓灰质炎病毒，A组和B组的柯萨奇病毒，回波病毒和Mengo病毒）和黄病毒（例如，丙型肝炎和牛 腹泻病毒）。 还提供了一种抑制微小核糖核酸病毒和黄病毒的方法，其包括向宿主施用有效量的本发明苯并咪唑化合物。
-
公开(公告)号：US5693661A
公开(公告)日：1997-12-02
申请号：US483651
申请日：1995-06-07
IPC分类号： A61K31/415 , A61K31/4184 , A61P11/00 , A61P31/12 , C07D235/30 , A61K31/535 , C07D413/04 , C07D417/04
CPC分类号： C07D235/30
摘要： Certain vinyl acetylene benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus.
摘要翻译： 某些乙烯基乙炔苯并咪唑化合物抑制微小核糖核酸病毒如鼻病毒，肠道病毒，心脏病毒，脊髓灰质炎病毒，A组和B组柯萨奇病毒，回波病毒和Mengo病毒的生长。
-
公开(公告)号：US08252923B2
公开(公告)日：2012-08-28
申请号：US12231982
申请日：2008-09-08
申请人： Robert Edward Babine , Shu-Hui Chen , Jason Eric Lamar , Nancy June Snyder , Xicheng Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Ivan Collado , Cristina Garcia-Paredes , Raymond Samuel Parker, III , Ling Jin , Deqi Guo , John Irvin Glass
发明人： Robert Edward Babine , Shu-Hui Chen , Jason Eric Lamar , Nancy June Snyder , Xicheng Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Ivan Collado , Cristina Garcia-Paredes , Raymond Samuel Parker, III , Ling Jin , Deqi Guo , John Irvin Glass
IPC分类号： C07D265/34 , C07D241/08 , C07D275/06 , C07D417/02 , C07D233/32 , C07D403/02 , C07D207/08 , C07D493/14 , C07C229/00
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及可用作蛋白酶抑制剂的肽模拟化合物，特别是作为丝氨酸蛋白酶抑制剂，更具体地，涉及丙型肝炎NS3蛋白酶抑制剂; 中间体; 它们的制备方法包括对中间体的新型置换步骤。 本发明还涉及药物组合物和使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染有关的生理病症的患者的方法。 还提供了药物组合，除一种或多种HCV丝氨酸蛋白酶抑制剂外还包含一种或多种表现出抗HCV活性的干扰素和/或一种或多种具有抗HCV活性的化合物和药学上可接受的载体，以及用于治疗或预防的方法 使用该组合物的患者中的HCV感染。 本发明还涉及用于治疗或预防患者HCV感染的试剂盒或药物包装。
-
公开(公告)号：US20120064034A1
公开(公告)日：2012-03-15
申请号：US13293812
申请日：2011-11-10
申请人： ROBERT EDWARD BABINE , SHU HUI CHEN , IVAN COLLADO , CRISTINA GARCIA-PAREDES , JOHN IRVIN GLASS , DEQI GUO , LING JIN , JASON ERIC LAMAR , RAYMOND SAMUEL PARKER, III , NANCY JUNE SNYDER , XICHENG DAVID SUN , YVONNE YEE MAI YIP , Q. MAY WANG , FRANTZ VICTOR , MARK JOSEPH TEBBE , ROBERT B. PERNI , LUC FARMER
发明人： ROBERT EDWARD BABINE , SHU HUI CHEN , IVAN COLLADO , CRISTINA GARCIA-PAREDES , JOHN IRVIN GLASS , DEQI GUO , LING JIN , JASON ERIC LAMAR , RAYMOND SAMUEL PARKER, III , NANCY JUNE SNYDER , XICHENG DAVID SUN , YVONNE YEE MAI YIP , Q. MAY WANG , FRANTZ VICTOR , MARK JOSEPH TEBBE , ROBERT B. PERNI , LUC FARMER
IPC分类号： A61K38/08 , C07K5/037 , A61K38/21 , C12N5/071 , C07C229/42 , C07D209/52 , C12N9/99 , C07K7/06 , A61K38/20
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
-
公开(公告)号：US20100137583A1
公开(公告)日：2010-06-03
申请号：US12231982
申请日：2008-09-08
申请人： Robert Edward Babine , Shu-Hui Chen , Jason Eric Lamar , Nancy June Snyder , Xicheng Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Ivan Collado , Cristina Garcia-Paredes , Raymond Samuel Parker, III , Ling Jin , Deqi Guo , John Irvin Glass
发明人： Robert Edward Babine , Shu-Hui Chen , Jason Eric Lamar , Nancy June Snyder , Xicheng Sun , Mark Joseph Tebbe , Frantz Victor , Q. May Wang , Yvonne Yee Mai Yip , Ivan Collado , Cristina Garcia-Paredes , Raymond Samuel Parker, III , Ling Jin , Deqi Guo , John Irvin Glass
IPC分类号： C07D265/34 , C07D265/32 , C07D241/08 , C07D275/06 , C07D417/02 , C07D233/32 , C07D403/02 , C07D207/08 , C07D493/14 , C07C229/00
CPC分类号： C07K7/02 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/212 , A61K38/215 , A61K45/06 , C07D209/02 , C07D209/52 , C07K5/0202 , C07K5/0205 , C07K5/06052 , C07K5/0808 , C07K5/101 , C07K5/1016 , C07K7/06 , C07K14/005 , C12N2770/24222 , Y02P20/55 , A61K2300/00
摘要： The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及可用作蛋白酶抑制剂的肽模拟化合物，特别是作为丝氨酸蛋白酶抑制剂，更具体地，涉及丙型肝炎NS3蛋白酶抑制剂; 中间体; 它们的制备方法包括对中间体的新型置换步骤。 本发明还涉及药物组合物和使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染有关的生理病症的患者的方法。 还提供了药物组合，除一种或多种HCV丝氨酸蛋白酶抑制剂外还包含一种或多种表现出抗HCV活性的干扰素和/或一种或多种具有抗HCV活性的化合物和药学上可接受的载体，以及用于治疗或预防的方法 使用该组合物的患者中的HCV感染。 本发明还涉及用于治疗或预防患者HCV感染的试剂盒或药物包装。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.059 秒)
